Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: A multicenter, randomized, double-blind study

Thrombosis Research

Volumn 119, Issue 1, 2007, Pages 85-91

  Sgarabotto, Mariapaola ^a   Baldini, Monica ^a   Dei Cas, Alessandra ^b   Manotti, Cesare ^c   Luciana Barilli, Angela ^b   Rinaldi, Maurizio ^a   Benassi, Luigi ^a   Bacchi Modena, Alberto ^a  

^a Department of Obstetrics   (Italy)

^b Parma Hospital Italy Parma   (Italy)

^c Department of Medicine 3 Parma University Italy Parma ^*  (Italy)

Author keywords

Coagulation; HRT (hormone replacement therapy); Menopause; Raloxifene

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; D DIMER; ESTRADIOL PLUS NORETHISTERONE ACETATE; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTEIN S; PROTHROMBIN; RALOXIFENE; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEMOSTASIS; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; MULTICENTER STUDY; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THERAPY EFFECT;

AGED; BODY MASS INDEX; CONTRACEPTIVES, ORAL, SYNTHETIC; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ESTRADIOL; ESTRIOL; FEMALE; HEMOSTASIS; HUMANS; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIME FACTORS;

EID: 33750820976     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.01.001     Document Type: Article

References (26)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288 (2002) 321-333
2. Cosman F., and Lindsay R. Selective estrogen receptor modulator: clinical spectrum. Endocr Rev 20 3 (1999) 418-434
3. Vehkavaara S., Silveira A., Hakala-Ala-Pietila T., Virkamaki A., Hovatta O., Hamsten A., et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 85 (2001) 619-625
4. Lowe G.D.O., Upton M.N., Rumley A., McConnachie A., St. J. O'Reilly D., Watt G.C.M., et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein. Thromb Haemost 86 (2001) 550-556
5. Love R.R., Mazess R.B., Barden H.S., Epstein S., Newcomb P.A., Jordan V.C., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326 (1992) 852-856
6. Kauffman R.F., and Bryant H.U. Selective estrogen receptor modulators. Drug News Perspect 8 (1995) 531-539
7. Yang N.N., Venugopalan M., Hardikar S., and Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273 (1996) 1222-1225
8. Blumenthal R.S., Baranowski B., and Dowsett S.A. Cardiovascular effects of raloxifene: the arterial and venous systems. Am Heart J 147 5 (2004) 784-789
9. Grady D., Ettinger B., Moscarelli E., Plouffe L., Sarkar S., Ciaccia A., et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 104 (2004) 837-844
10. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powless T.J., Cauley J.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281 (1999) 2189-2197
11. Høibraaten E., Qvigstad E., Andersen T.O., Mowinckel M.C., and Sandset P.M. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism-results from a randomized, double-blind, clinical trial. Thromb Haemost 85 (2001) 775-781
12. Van Baal W.M., Emeis J.J., Van der Mooren M.J., Kessel H., Kenemans P., and Stehouwer C.D. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost 83 (2000) 29-34
13. Gaudio A., and Morabito N. Pharmacological management of severe postmenopausal osteoporosis. Drugs Aging 22 5 (2005) 405-417
14. Urano T. Effects of estrogen and selective estrogen receptor modulators on osteoporosis. Clin Calcium 15 4 (2005 (Apr)) 591-595
15. Daly E., Vessey M.P., Painter R., and Hawkins M.M. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet 348 9033 (1996 (Oct 12)) 1027
16. Jick H., Derby L.E., Myers M.W., Vasilakis C., and Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens. Lancet 348 9033 (1996 (Oct 12)) 981-983
17. Cushman M., Meilahn E.N., Psaty B.M., Kuller L.H., Dobs A.S., and Tracy R.P. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 4 (1999) 893-899
18. Davidson M.H., Maki K.C., Marx P., Maki A.C., Cyrowski M.S., Nanavati N., et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 160 21 (2000) 3315-3325
19. Post M.S., Christella M., Thomassen L.G., van der Mooren M.J., van Baal W.M., Rosing J., et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thombosis: a randomized, placebo-controlled study in post-menopausal women. Arterioscler Thromb Vasc Biol 23 6 (2003) 1116-1121
20. Abdollahi M., Cushman M., and Rosendaal F.R. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 89 3 (2003) 493-498
21. Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279 18 (1998) 1445-1451
22. Wells M.J., Sheffield W.P., and Blajchman M.A. The clearance of thrombin-antithrombin and related serpin-enzyme complexes from the circulation: role of various hepatocyte receptors. Thromb Haemost 81 (1999) 325-337
23. de Valk-de Roo G.W., Stehouwer C.D.A., Meijer P., Mijatovic V., Kluft C., Kenemans P., et al. Both raloxifene and estrogen reduce major cardiovascular risk factor in healthy postmenopausal women. A 2-years, placebo-controlled study. Arterioscler Thromb Vasc Biol (1999) 2993-3000
24. Cosman F., Baz-Hecht M., Cushman M., Vardy M.D., Cruz J.D., Nieves J.W., et al. R. Short-term effects of estrogen, tamoxifen, and raloxifene on hemostasis: a randomised-controlled study and review of the literature. Thromb Res 116 1 (2005) 1-13
25. Herrington D.M., and Potvin Klein K. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Women's Health Issues 11 2 (2001) 95-102
26. Teede H.J., McGrath B.P., Smolich J.J., Malan E., Kotsopoulos D., Liang Y.L., et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol (2000 (May)) 1404-1409